Slight reduction seen in major cardiovascular events; very low certainty of serious adverse events reported<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, April 8, 2024 (HealthDay News) — Salt substitution may reduce all-cause or cardiovascular mortality, according to a review published online April 9 in the Annals of Internal Medicine<\/em>.<\/p>\n Hannah Greenwood, from Bond University in Queensland, Australia, and colleagues examined the long-term effects of salt substitution on cardiovascular outcomes in a review of 16 randomized controlled trials, eight of which reported on primary outcomes, including mortality, major cardiovascular events (MACE), and adverse events at six months or longer.<\/p>\n Seven of the trials included populations of older age and\/or with higher cardiovascular risk than average. The researchers found that salt substitution in this population may reduce the risk for all-cause mortality and cardiovascular mortality (rate ratios [95 percent confidence intervals], 0.88 [0.82 to 0.93] and 0.83 [0.73 to 0.95], respectively; low certainty). A slight reduction in MACE was seen with salt substitution (rate ratio, 0.85; 95 percent confidence interval, 0.71 to 1.00; very low certainty), and there was very low-certainty evidence of serious adverse events (risk ratio, 1.04; 95 percent confidence interval, 0.87 to 1.25).<\/p>\n “Salt substitution is a promising low-cost and scalable nondrug intervention that may reduce mortality outcomes with very low-certainty evidence of reducing MACE and without increased risk for serious harms,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n